$ROSG very low float recovery climb $0.74 Nasdaq
Post# of 98044
Posted On: 11/20/2016 5:16:14 PM
$ROSG very low float recovery climb $0.74
Nasdaq GM
Website
20-F 3/23/16
Shares Outstanding 20.87M
Float 19.63M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short 907.84k
Short Ratio 5.64
Short % of Float 4.35%
Shares Short (prior month) 838.1k
Headlines
and filings
Rosetta Genomics Ltd. develops and commercializes microRNA-based and other molecular diagnostics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including RosettaGX Cancer Origin, a diagnostic for the identification of metastatic cancer; mi-LUNG, a lung cancer classification test for cytology samples; mi-KIDNEY, a kidney tumor classification test for pathology samples; and RosettaGX Reveal, a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate (FNA) samples. It is also developing RosettaGX Reveal V2, a microRNA-based assay for the diagnosis of indeterminate thyroid FNAs; and tissue-based microRNA biomarkers to develop a test for the risk stratification of patients with non-muscle-invasive bladder cancer. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.
Nasdaq GM
Website
20-F 3/23/16
Shares Outstanding 20.87M
Float 19.63M
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short 907.84k
Short Ratio 5.64
Short % of Float 4.35%
Shares Short (prior month) 838.1k
Headlines
and filings
Rosetta Genomics Ltd. develops and commercializes microRNA-based and other molecular diagnostics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. The company offers diagnostic tests, including RosettaGX Cancer Origin, a diagnostic for the identification of metastatic cancer; mi-LUNG, a lung cancer classification test for cytology samples; mi-KIDNEY, a kidney tumor classification test for pathology samples; and RosettaGX Reveal, a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate (FNA) samples. It is also developing RosettaGX Reveal V2, a microRNA-based assay for the diagnosis of indeterminate thyroid FNAs; and tissue-based microRNA biomarkers to develop a test for the risk stratification of patients with non-muscle-invasive bladder cancer. The company distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.
(0)
(0)Scroll down for more posts ▼